Pfizer to Appeal UK Judgment on COVID-19 Vaccine Patent Dispute
In a closely watched development in the ongoing legal batter over mRNA vaccine technology, Pfizer and its German partner BioNTech have announced their intention to continue challenging a UK court ruling that found their COVID-19 vaccine infringed on a patent held by rival pharmaceutical company Moderna.
The UK Court of Appeal today upheld a previous decision by the High Court, ruling that Moderna's patent covering aspects of its mRNA technology was valid and not obvious, rejecting Pfizer's latest attempt to invalidate the claim. The decision marks a significant victory for Moderna in the UK, though the broader global dispute between the pharmaceutical giants remains far from over.
Background
The legal dispute revolves around key components of mRNA technology, which became central to the rapid development and deployment of COVID-19 vaccines during the global pandemic. Moderna holds a number of patents relating to the use and delivery of messenger RNA (mRNA) for therapeutic and vaccine purposes. In 2022, Moderna sued Pfizer and BioNTech in several jurisdictions, including the UK, alleging that the rival vaccine developers had infringed its patents in the creation of their own vaccine, Comirnaty.
Pfizer and BioNTech have consistently denied the claims, arguing that their vaccine was developed independently and relied on distinct innovations. In the UK case, the companies attempted to invalidate Moderna's patent by arguing that it lacked inventiveness and would have been obvious to skilled researchers at the time.
However, the UK High Court ruled in favour of Moderna in 2023, finding that the patent in question did involve an inventive step and could not be dismissed as obvious in light of the prior art. Pfizer appealed, but the Court of Appeal has now confirmed that ruling, stating that the High Court judge was correct in their analysis.
Pfizer's Response
Following the judgment, Pfizer and BioNTech issued a joint statement expressing disappointment with the decision but reaffirming their commitment to challenging what they see as an overly broad and unfounded patent claim.
"We respectfully disagree with the Court's interpretation and continue to believe that Moderna's patent is invalid," the companies said. "We are considering further options for appeal and will continue to defend our vaccine, which was developed in record time to help address a global public health emergency."
The companies now face the possibility of substantial financial liability, should Moderna pursue damages or royalties for sales of the Pfizer-BioNTech vaccine in the UK and potentially elsewhere. However, any financial consequences will depend on the outcome of future proceedings and whether Pfizer succeeds in overturning the ruling in the UK Supreme Court.
Wider Implications
This legal battle is part of a broader web of disputes over intellectual property rights in mRNA technology, a field that has seen a surge in interest and investment due to the success of COVID-19 vaccines. Moderna is also engaged in similar litigation in the United States and Germany, and the UK ruling could influence how courts in those jurisdictions approach the issues of obviousness, patent scope, and infringement.
While the vaccines were initially distributed under agreements designed to expedite pandemic response, the transition to commercialisation has revived longstanding tensions over IP ownership in biotech. The outcome of these disputes could shape the landscape for future mRNA therapies well beyond COVID-19.
What Next?
Pfizer and BioNTech are expected to seek permission to appeal to the UK Supreme Court. Whether the Court agrees to hear the case will depend on whether it raises questions of legal principle or public importance.
In the meantime, this ruling affirms the strength of Moderna's patent portfolio in the UK and may embolden other patent holders in the biotech sector seeking to enforce their rights. For pharmaceutical companies navigating the post-pandemic landscape, the case is a stark reminder that IP strategy remains as critical as scientific innovation.
Make an Enquiry Now
To speak to one of our intellectual property experts, call 0131 478 4724 or complete an Online Enquiry.
We have helped hundreds of individuals and businesses.
